EPF position on value/pricing innovative medicines
EPF launchesposition paper outlining the key concerns of the EU patient community regarding inequities in access related to current pricing models.
The statement highlights nine core principles that the pharmaceutical industry, national decision-makers and the EU Institutions should commit to in order to ensure equitable access to treatment based on needs, not means, while supporting the long-term sustainability of our health systems.
Calling for a new collaborative approach linked to the added-value of a medicines for patients and the centrality of the patient perspective throughout the medicines lifecycle, the paper outlines our vision of timely access to accurate diagnosis and appropriate treatment. Such access can not only improves patient health and well-being but can also offset significant costs to the health and social systems as a result of avoidable exacerbation of health conditions.